Simultaneous serum aquaporin-4 antibody and CSF NMDA receptor antibody–positive encephalitis

por Orengo, James P., Pekmezci, Melike, Cree, Bruce A.C.
Publicado 2015

Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis...

por Cree, Bruce A. C., Greenberg, Benjamin, Cameron, Chris, Weinshenker, Brian G.
Publicado 2022

The Gut Microbiome in Neuromyelitis Optica

por Zamvil, Scott S., Spencer, Collin M., Baranzini, Sergio E., Cree, Bruce A. C.
Publicado 2017

Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO

por Gelfand, Jeffrey M., Cotter, Jennifer, Klingman, Jeffrey, Huang, Eric J., Cree, Bruce A.C.
Publicado 2014

Acute liver injury in a Glatopa-treated patient with MS

por Sabatino, Joseph J., Mehta, Neil J., Kakar, Sanjay, Zamvil, Scott S., Cree, Bruce A.C.
Publicado 2017

Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens

por Cree, Bruce A. C., Spencer, Collin M., Varrin‐Doyer, Michel, Baranzini, Sergio E., Zamvil, Scott S.
Publicado 2016

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate

por Spencer, Collin M., Crabtree-Hartman, Elizabeth C., Lehmann-Horn, Klaus, Cree, Bruce A.C., Zamvil, Scott S.
Publicado 2015

Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS

por Harris, Sarah, Tran, Jonathan Q., Southworth, Harry, Spencer, Collin M., Cree, Bruce A.C., Zamvil, Scott S.
Publicado 2020

Phase 1 Evaluation of Elezanumab (Anti–Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants

por Kalluri, Hari V., Rosebraugh, Matthew R., Misko, Thomas P., Ziemann, Adam, Liu, Wei, Cree, Bruce A. C.
Publicado 2022

Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review

por Block, Valerie A. J., Pitsch, Erica, Tahir, Peggy, Cree, Bruce A. C., Allen, Diane D., Gelfand, Jeffrey M.
Publicado 2016

Progressive multifocal leukoencephalopathy after fingolimod treatment

por Berger, Joseph R., Cree, Bruce A., Greenberg, Benjamin, Hemmer, Bernhard, Ward, Brian J., Dong, Victor M., Merschhemke, Martin
Publicado 2018

Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker

por Aktas, Orhan, Smith, Michael A., Rees, William A., Bennett, Jeffrey L., She, Dewei, Katz, Eliezer, Cree, Bruce A. C.
Publicado 2021

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis

por Cohan, Stanley L., Benedict, Ralph H. B., Cree, Bruce A. C., DeLuca, John, Hua, Le H., Chun, Jerold
Publicado 2022

Aquaporin 4-Specific T Cells in Neuromyelitis Optica Exhibit a Th17 Bias and Recognize Clostridium ABC Transporter

por Varrin-Doyer, Michel, Spencer, Collin M, Schulze-Topphoff, Ulf, Nelson, Patricia A, Stroud, Robert M, C Cree, Bruce A, Zamvil, Scott S
Publicado 2012

Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial

por Cree, Bruce A.C., Arnold, Douglas L., Cascione, Mark, Fox, Edward J., Williams, Ian M., Meng, Xiangyi, Schofield, Lesley, Tenenbaum, Nadia
Publicado 2018

Secondary Progressive Multiple Sclerosis: New Insights

por Cree, Bruce A.C., Arnold, Douglas L., Chataway, Jeremy, Chitnis, Tanuja, Fox, Robert J., Pozo Ramajo, Angela, Murphy, Niamh, Lassmann, Hans
Publicado 2021

Integration of epigenetic and genetic profiles identifies multiple sclerosis disease-critical cell types and genes

por Ma, Qin, Shams, Hengameh, Didonna, Alessandro, Baranzini, Sergio E., Cree, Bruce A. C., Hauser, Stephen L., Henry, Roland G., Oksenberg, Jorge R.
Publicado 2023

Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD

por Das, Gitanjali, Damotte, Vincent, Gelfand, Jeffrey M., Bevan, Carolyn, Cree, Bruce A.C., Do, Lynn, Green, Ari J., Hauser, Stephen L., Bove, Riley
Publicado 2018

pRNFL as a marker of disability worsening in the medium/long term in patients with MS

por Cordano, Christian, Nourbakhsh, Bardia, Devereux, Michael, Damotte, Vincent, Bennett, Daniel, Hauser, Stephen L., Cree, Bruce A. C., Gelfand, Jeffrey M., Green, Ari J.
Publicado 2018

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials

por Harris, Sarah, Comi, Giancarlo, Cree, Bruce A. C., Arnold, Douglas L., Steinman, Lawrence, Sheffield, James K., Southworth, Harry, Kappos, Ludwig, Cohen, Jeffrey A.
Publicado 2021